Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment

SummaryActive case finding for osteoporosis is used to identify patients at high fracture risk who may benefit from preventive drug treatment. We investigated the relative weight that women place on various aspects of preventive drugs in a discrete choice experiment. Our patients said they were prepared to take preventive drugs even if side effects were expected.IntroductionActive case finding for osteoporosis is used to identify patients who may benefit from preventive drugs. We aimed to elicit the relative weight that patients place on various aspects of preventive drug treatment for osteoporosis.MethodsWe designed a discrete choice experiment, in which women had to choose between drug profiles that differed in five treatment attributes: effectiveness, side effects (nausea), total treatment duration, route of drug administration, and out-of-pocket costs. We included 120 women aged 60 years and older, identified by osteoporosis case finding in 34 general practices in the Netherlands. A conditional logit regression model was used to analyse the relative importance of treatment attributes, the trade-offs that women were willing to make between attributes, and their willingness to pay.ResultsAll treatment attributes proved to be important for women’s choices. A reduction of the relative 10-year risk of hip fracture by 40% or more by the drug was considered to compensate for nausea as a side effect. Women were prepared to pay an out-of-pocket contribution for the currently available drug treatment (bisphosphonate) if the fracture risk reduction was at least 12%.ConclusionsWomen identified by active osteoporosis case finding stated to be prepared to take preventive drugs, even if side effects were expected and some out-of-pocket contribution was required.

[1]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[2]  Nikos Maniadakis,et al.  Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[4]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[5]  M Ryan,et al.  Eliciting public preferences for healthcare: a systematic review of techniques. , 2001, Health technology assessment.

[6]  Meunier Pj.  Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. , 1999 .

[7]  M. Ryan,et al.  Using discrete choice modelling in priority setting: an application to clinical service developments. , 2000, Social science & medicine.

[8]  F. Korkusuz,et al.  Burden of osteoporosis. , 2006, Clinical orthopaedics and related research.

[9]  Anna Lee,et al.  A Comparison of Patients’ and Health Care Professionals’ Preferences for Symptoms During Immediate Postoperative Recovery and the Management of Postoperative Nausea and Vomiting , 2005, Anesthesia and analgesia.

[10]  D. Hensher,et al.  Stated Choice Methods: Analysis and Applications , 2000 .

[11]  P. Hilliquin,et al.  Characterisation of Patients with Postmenopausal Osteoporosis in French Primary Healthcare , 2007, Drugs & aging.

[12]  S. Silverman.  Quality-of-life issues in osteoporosis , 2005, Current rheumatology reports.

[13]  L. Melton,et al.  The worldwide problem of osteoporosis: insights afforded by epidemiology. , 1995, Bone.

[14]  J. Louviere,et al.  Using discrete choice experiments to investigate subject preferences for preventive asthma medication , 2007, Respirology.

[15]  L. Fraenkel,et al.  Patient treatment preferences for osteoporosis. , 2006, Arthritis and rheumatism.

[16]  M. Ryan,et al.  Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. , 2004, The Journal of urology.

[17]  P. Meunier,et al.  EVIDENCE‐BASED MEDICINE AND OSTEOPOROSIS: A COMPARISON OF FRACTURE RISK REDUCTION DATA FROM OSTEOPOROSIS RANDOMISED CLINICAL TRIALS , 1999, International journal of clinical practice.

[18]  M. Sculpher,et al.  Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment , 2004, BMJ : British Medical Journal.

[19]  Women's preferences for prevention of bone loss. , 2005, The Journal of rheumatology.

[20]  M Ryan,et al.  Using conjoint analysis to assess women's preferences for miscarriage management. , 1997, Health economics.

[21]  E. Barrett-Connor,et al.  Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. , 1997, Archives of internal medicine.

[22]  C. Cooper,et al.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. , 1997, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[23]  L. Kleinman,et al.  Willingness to Pay for Sensory Attributes of Intranasal Corticosteroids Among Patients With Allergic Rhinitis , 2006, Journal of managed care pharmacy : JMCP.

[24]  R. Bartl,et al.  [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. , 2006, Deutsche medizinische Wochenschrift.

[25]  M Ryan,et al.  Using conjoint analysis to elicit preferences for health care , 2000, BMJ : British Medical Journal.

[26]  C. Cooper,et al.  Guidelines for diagnosis and management of osteoporosis , 2005, Osteoporosis International.

[27]  P. Hadji,et al.  Adhärenz mit täglichen und wöchentlichen oralen Bisphosphonaten in der Osteoporosetherapie , 2006 .

[28]  D. Gyrd-Hansen,et al.  Analysing public preferences for cancer screening programmes. , 2001, Health economics.

[29]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.